电子T1肺transplan RT老杂志文章tation for sarcoidosis: outcome and prognostic factors JF European Respiratory Journal JO Eur Respir J FD European Respiratory Society SP 2003358 DO 10.1183/13993003.03358-2020 VO 58 IS 2 A1 Le Pavec, Jérôme A1 Valeyre, Dominique A1 Gazengel, Pierre A1 Holm, Are M. A1 Schultz, Hans Henrik A1 Perch, Michael A1 Le Borgne, Aurélie A1 Reynaud-Gaubert, Martine A1 Knoop, Christiane A1 Godinas, Laurent A1 Hirschi, Sandrine A1 Bunel, Vincent A1 Laporta, Rosalia A1 Harari, Sergio A1 Blanchard, Elodie A1 Magnusson, Jesper M. A1 Tissot, Adrien A1 Mornex, Jean-François A1 Picard, Clément A1 Savale, Laurent A1 Bernaudin, Jean-François A1 Brillet, Pierre-Yves A1 Nunes, Hilario A1 Humbert, Marc A1 Fadel, Elie A1 Gottlieb, Jens YR 2021 UL //www.qdcxjkg.com/content/58/2/2003358.abstract AB Study question In patients with sarcoidosis, past and ongoing immunosuppressive regimens, recurrent disease in the transplant and extrapulmonary involvement may affect outcomes of lung transplantation. We asked whether sarcoidosis lung phenotypes can be differentiated and, if so, how they relate to outcomes in patients with pulmonary sarcoidosis treated by lung transplantation.Patients and methods We retrospectively reviewed data from 112 patients who met international diagnostic criteria for sarcoidosis and underwent lung or heart–lung transplantation between 2006 and 2019 at 16 European centres.Results Patient survival was the main outcome measure. At transplantation, median (interaquartile range (IQR)) age was 52 (46–59) years; 71 (64%) were male. Lung phenotypes were individualised as follows: 1) extended fibrosis only; 2) airflow obstruction; 3) severe pulmonary hypertension (sPH) and airflow obstruction; 4) sPH, airflow obstruction and fibrosis; 5) sPH and fibrosis; 6) airflow obstruction and fibrosis; 7) sPH; and 8) none of these criteria, in 17%, 16%, 17%, 14%, 11%, 9%, 5% and 11% of patients, respectively. Post-transplant survival rates after 1, 3, and 5 years were 86%, 76% and 69%, respectively. During follow-up (median (IQR) 46 (16–89) months), 31% of patients developed chronic lung allograft dysfunction. Age and extended lung fibrosis were associated with increased mortality. Pulmonary fibrosis predominating peripherally was associated with short-term complications.Answer to the study question Post-transplant survival in patients with pulmonary sarcoidosis was similar to that in patients with other indications for lung transplantation. The main factors associated with worse survival were older age and extensive pre-operative lung fibrosis.Post-transplant survival in patients with pulmonary sarcoidosis was similar to that in patients with other indications for lung transplantation. The main factors associated with worse survival were older age and extensive pre-operative lung fibrosis. https://bit.ly/2XBfJd6